Comparison of Dyslipidemia Among Diabetics Versus Non Diabetics in Haemodialysis Patients

Not yet recruiting

• Conditions: Dyslipidemias
• Interventions: Procedure: haemodialysis

• Registration Number: NCT06401122
• Lead Sponsor: Assiut University

Brief Summary

* How dyslipidemia common among Diabetic and non- Diabetic Haemodialysis patients.

* How differ dyslipidemia types among Diabetic and non- Diabetic in Haemodialysis patients. (Qualitative difference).

Detailed Description

Diabetes mellitus (DM) is a metabolic disease , a consequence of defects in insulin action, secretion, or both, and there are complications associated with it, such as nephropathy, retinopathy, neuropathy, cardiovascular complications ,cerebrovascular and peripheral arterial disease. Diabetic nephropathy, which occurs in about one third of type 2 diabetic patients, is the most common factor leading to end-stage renal disease (ESRD) . A very common metabolic abnormality associated with diabetes is dyslipidemia, which is characterized by a spectrum of quantitative and qualitative changes in lipids and lipoproteinsSeveral previous studies have pursued linking blood glucose levels to serum lipid activities. The etiology of dyslipidemia appears to be centered on the increased large TAG-rich very low-density lipoprotein-cholesterol (VLDL-C) and its impaired clearance. American diabetic association (ADA) defines dyslipidemia as hypercholesterolemia ≥200 mg/dl of serum total cholesterol, hypertriglyceridemia ≥150 mg/dl of serum triglyceride, reduced high density lipoprotein cholesterol (HDL-C) \<40 mg/dl for men and \<50 mg/dl for women, elevated low density lipoprotein cholesterol (LDL-C) ≥70 mg/dl and high TC to HDL-C ratio of ≥4.5. Normal plasma lipids and lipoprotein metabolism is critical for cellular cholesterol homeostasis and protection against atherosclerosis, renal disease and other complication . A study found that people with high blood pressure and overweight or obesity have a higher risk of developing dyslipidemia ,Early detection and effective control of blood lipid levels can reduce the morbidity and mortality of CVD in patients with DM. Therefore, it is important to determine the factors associated with dyslipidemia.

Study Timeline

• Status Verified: 2024-05
• Study First Submitted: 2024-05-02
• Study First Submitted QC: 2024-05-02
• Last Update Submitted: 2024-05-02
• Study First Posted: 2024-05-06
• Last Update Posted: 2024-05-06
• Study Start: 2024-06-01
• Primary Completion: 2025-06-01
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patients aged between 18 and 60 years.
• Patients undergoing regular conventional Haemodialysis for more than 6 months

Exclusion Criteria

• Peritoneal Dialysis
• Haemodiafilteration
• Acute Kidney Injury
• Nephrotic syndrome
• Hypothyroidism
• Familial hypertriglyceridemia.
• Acute pancreatitis
• Connective tissue disease.
• Decompensated liver disease
• Active malignancy.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
diabetic dialysis patients	haemodialysis	fifty diabetic patients on regular haemodialysis more than 6 months
Non-diabetic dialysis patients	haemodialysis	fifty Non-diabetic patients on regular haemodialysis more than 6 months

Primary Outcome Measures

Name	Time	Method
dyslipidemia prevalence among Diabetic versus non- Diabetic Haemodialysis patients	baseline	haemodialysis patients for more than six months, and is with diabetes related to affect prevalance of dyslipidemia among these patients